Phase III trial data supports current standard 12-month adjuvant trastuzumab for HER2-positive breast cancer

Temporary ovarian suppression with hormone analogue may preserve fertility during breast cancer chemotherapy

Two years of extended anastrozole therapy as effective as five

Tandem duplicator phenotypes define 50% of triple negative breast cancers

Updated genomic screening tool for life-time breast cancer risk

Temporary ovarian suppression with hormone analogue may preserve fertility during breast cancer chemotherapy

Acupuncture significantly reduces joint pain for breast cancer patients

Immunotherapy shows early promise for patients with trastuzumab-resistant breast cancer

HR–positive advanced breast cancer: Ribociclib improved PFS for pre and perimenopausal women

HER2low invasive breast cancer: Trastuzumab offers no improvement for invasive disease free survival

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer

Increasing the dose intensity of chemotherapy may lower the risk of breast cancer recurrence and death